Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | AMG 340 |
| Synonyms | |
| Therapy Description |
AMG 340 is a T-cell engager that binds to PSMA and CD3, which potentially induces antitumor activity (J Clin Oncol 42, 2024 (suppl 16; abstr e14587). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| AMG 340 | AMG-340|AMG340|TNB-585|TNB 585 | CD3 Antibody 119 PSMA Antibody 22 | AMG 340 is a T-cell engager that binds to PSMA and CD3, which potentially induces antitumor activity (J Clin Oncol 42, 2024 (suppl 16; abstr e14587). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04740034 | Phase I | AMG 340 | A Study of AMG 340 in Subjects With Metastatic Castrate-Resistant Prostate Carcinoma | Terminated | USA | 0 |